IRCT20131125015536N8 IRCT 2019-06-19 Tehran University of Medical Sciences Effect of Nano-curcumin in Coronary Slow Flow Phenomenon The study of the effect of nano-curcumin supplementation on biomarkers of endothelial function and inflammation in overweight or obese patients with Coronary Slow Flow Phenomenon 2019-07-22 anticipated 42 Complete https://irct.ir/trial/40083 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Study participants will be assigned to nano-curcumin or placebo groups by stratified permuted block randomization. As the first step, we will have stratified randomization for gender. Then, either points 1 or 0 will be given to various confounding factors in this study. For example, having family history of coronary artery disease: 1 and no family history of CAD: 0, diabetes mellitus:1 , no diabetes mellitus: 0 hypertention: 1, no hypertention: 0 dyslipidemia: 1 , no dyslipidemia: 0 smoker:1 , non-smoker:0 Using any of these medications: ACE-I, ARBs, beta-blockers, statins, anticoagulants, calcium channel blockers and nitrates: 0, no use: 1. The sum of these points will be a score between 0 to 6 for each patient. The patients with scores 3 and below will be considered as low risk and patients with scores equivalent to or higher than 4 will be considered as high risk for condition of the disease and then, they will go through stratified randomization according to their risk level. Patients are randomized by using permuted blocks of size 4 and 6 (specific random number tables will be used), Blinding description: Using identical boxes with either A or B code labels for nano-curcumin and placebo supplements, will help to blind both patients and investigators. N/A Coronary Slow Flow Phenomenon (CSFP). Intervention 1: Intervention group: Dietary supplement nano-curcumin 80 mg one capsule daily (Exir Nano Sina Co.). Intervention 2: Control group: Placebo supplement one capsule daily (Exir Nano Sina Co.). No - There is not a plan to make this available Justification or reason for not sharing IPD is "There is no further information"